T
Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter
Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a
protein found on dendritic cells, activated B cells and monocytes. The
activated protein induces T-cell proliferation and cytokine production. T-cell
proliferation and cytokine production is induced by the binding of CD28.
T
lymphocyte Activation Antigen CD80
(Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline
Target constitutes close to 13 molecules. Out of which approximately 11
molecules are developed by companies and remaining by the
universities/institutes. The molecules developed by companies in
Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery
stages are 1, 1, 1, 2, 4 and 2 respectively.
Similarly,
the universities portfolio in Preclinical stages comprises 2 molecules,
respectively. Report covers products from therapy areas Immunology, Oncology,
Musculoskeletal Disorders, Dermatology, Genito Urinary System And Sex Hormones,
Metabolic Disorders, Ophthalmology and Respiratory which include indications
Rheumatoid Arthritis, Autoimmune Disorders, Acute Myelocytic Leukemia (AML,
Acute Myeloblastic Leukemia), Alopecia, Breast Cancer, Dermatomyositis, Diffuse
Large B-Cell Lymphoma, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus
Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener Polyangiitis),
Hepatocellular Carcinoma, Interstitial Lung Diseases (Diffuse Parenchymal Lung
Disease), Juvenile Rheumatoid Arthritis, Lupus Nephritis, Myasthenia Gravis,
Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA),
Polymyositis/Idiopathic Inflammatory Myopathy, Renal Cell Carcinoma, Sicca
Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis
(Scleroderma), Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes),
Uveitis and Vitiligo.
The
latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H1 2018,
outlays comprehensive information on the T Lymphocyte Activation Antigen CD80
(Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted
therapeutics, complete with analysis by indications, stage of development,
mechanism of action (MoA), route of administration (RoA) and molecule type. It also
reviews key players involved in T Lymphocyte Activation Antigen CD80
(Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted
therapeutics development with respective active and dormant or discontinued
projects.
The
report is built using data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
The
report provides a snapshot of the global therapeutic landscape for T Lymphocyte
Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor
B7.1 or CD80)
The
report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or
CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development
by companies and universities/research institutes based on information derived
from company and industry-specific sources
The
report covers pipeline products based on various stages of development ranging
from pre-registration till discovery and undisclosed stages
The
report features descriptive drug profiles for the pipeline products which
includes, product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
The
report reviews key players involved in T Lymphocyte Activation Antigen CD80
(Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted
therapeutics and enlists all their major and minor projects
The
report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen
or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on
mechanism of action (MoA), route of administration (RoA) and molecule type
The
report summarizes all the dormant and discontinued pipeline projects
The
report reviews latest news and deals related to T Lymphocyte Activation Antigen
CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted
therapeutics
To know more, click on the link below:
Related Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204
No comments:
Post a Comment